Treatment and Prophylaxis for Gastroesophageal Reflux Disease

• US 20160089405A1
• Filed: 09/24/2015
• Published: 03/31/2016
• Est. Priority Date: 09/26/2014
• Status: Active Grant

• Current Assignee: NuBiome Inc.
• Original Assignee: NuBiome Inc.
• Inventors: Lue, Brian C.
• Granted Patent: US 9,925,225 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 38/482 Serine endopeptidases (3.4.21)
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: C12Y 304/21026 Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
• CPC Class Codes: C12Y 304/21062 Subtilisin (3.4.21.62)
• CPC Class Codes: C12Y 304/24 Metalloendopeptidases (3.4.24)

Abstract

An embodiment is a method of preventing, mitigating or treating Gastroesophageal Reflux Disease (GERD) that includes administering an effective amount of a medicament comprised of the Lactobacillus bulgaricus B-30892 strain and/or bioactive compounds from its supernatant to a human to prevent, mitigate or treat GERD.

Claims

1. A method of preventing, mitigating or treating Gastroesophageal Reflux Disease (GERD) comprises:

administering an effective amount of a medicament comprised of Lactobacillus bulgaricus B-30892 to a human to prevent, mitigate or treat GERD.

2. The method of claim 1 wherein the medicament further comprises oligopeptidase F (PepF).

3. The method of claim 1 wherein the medicament further comprises endopeptidase O (PepO).

4. The method of claim 1 wherein the medicament further comprises endopeptidase O2 (PepO2).

5. The method of claim 1 wherein the medicament further comprises subtilisin.